Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy volunteers test new chikungunya drug in early safety trial

NCT ID NCT04441905

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 36 times

Summary

This early-stage study tested a single dose of an experimental drug called SAR440894 in 42 healthy adults to see if it is safe. The drug is being developed to fight chikungunya virus infection, but this trial did not involve infected people. The main goal was to check for side effects and how the body processes the drug, not to treat or cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit

    Durham, North Carolina, 27710, United States

  • PPD - Austin Clinical Research Unit

    Austin, Texas, 78744-1645, United States

  • Pharmaceutical Product Development - Orlando Clinical Research Unit

    Orlando, Florida, 32806, United States

Conditions

Explore the condition pages connected to this study.